Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nature Immunology|October 16, 2019
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backupsLawrence P Andrews, Hiroshi Yano, Dario A A Vignali
European Journal of Immunology|May 29, 2015
Inhibitory receptors as targets for cancer immunotherapyMeghan E Turnis, Lawrence P Andrews, Dario A A Vignali
Immunology|May 16, 2019
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunityHiroshi Yano, Lawrence P Andrews, Creg J Workman, et al.
Immunological Reviews|March 5, 2017
LAG3 (CD223) as a cancer immunotherapy targetLawrence P Andrews, Ariel E Marciscano, Charles G Drake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2022
Molecular Pathways and Mechanisms of LAG3 in Cancer TherapyLawrence P Andrews, Anthony R Cillo, Lilit Karapetyan, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 15, 2017
Treg-recruiting microspheres prevent inflammation in a murine model of dry eye diseaseMichelle L Ratay, Andrew J Glowacki, Stephen C Balmert, et al.
Immunity|February 14, 2016
Interleukin-35 Limits Anti-Tumor ImmunityMeghan E Turnis, Deepali V Sawant, Andrea L Szymczak-Workman, et al.
Immunity|September 22, 2021
A Cre-driven allele-conditioning line to interrogate CD4+ conventional T cellsLawrence P Andrews, Kate M Vignali, Andrea L Szymczak-Workman, et al.
Science Immunology|July 19, 2020
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 sheddingLawrence P Andrews, Ashwin Somasundaram, Jessica M Moskovitz, et al.
Cell|August 9, 2024
LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunityLawrence P Andrews, Samuel C Butler, Jian Cui, et al.
Pageof 2